anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing sun dried salt and Eclipta prostrate extract for treating or preventing diabetes is provided to suppress protein tyrosine phosphatase(PTP1B) and α-glucosidase and treat diabetes without diabetes. CONSTITUTION: A composition for preventing or treating diabetes contains salt and Eclipta prostrate extract as an active ingredient. The salt is sun dried salt. The Eclipta prostrate extract is isolated using water, 50-100% of alcohol of 1-4 carbon atoms, athylacetate, hexane or dichloromethane. The content of salt and Eclipta prostrate extract is 1:1~30:1 based on weight part. A food composition for relieving or preventing diabetes contains salt and Eclipta prostrate extract as an active ingredient. The food composition is used in the form of food, beverage, gum, team vitamin, complex or functional food.
The invention relates to a computer-implemented method for determining imaging parameter values for controlling a medical technology device in the detection of a first image data set. In this case, the first image data set is provided for transmission from the medical device to a remotely situated device. The method comprises method steps of receiving (REC-1) and/or determining (DET-1) a transmission parameter value. Here, the transmission parameter value includes information on: what image information is relevant for the first image data set to be transmitted. The method further comprises a method step of determining (DET-2) the imaging parameter values from the transmission parameter values. The method further comprises a method step of providing (PROV-1) the imaging parameter values.
Limitations in physical function (PF) are related to decreased quality of life and are predictive of disability, nursing home admission, increased healthcare costs, and mortality in older adults. Structured physical activity has been shown to prevent mobility disability among those with physical function limitations, though community-based programs are needed, particularly in underserved communities. The purpose of this study is to pilot test a tailored physical activity intervention in churches in Chicago's West Side through an existing community-based participatory research partnership. The investigators previously found high rates of physical function limitations in these communities, and through qualitative research have identified intervention components that may aid in promoting physical activity among community members with physical function limitations. The primary aim is test the intervention in a 16 week, proof-of-concept study in 20 participants who are ambulatory but have PF limitations. The group-based physical activity intervention will take place in a large common area of a church. For feasibility the investigators will be testing the intervention in one church. The intervention will be delivered over 16 weeks, with assessments at baseline and 16 weeks.
PURPOSE:To provide the titled external drug containing allithiamine as an active component, directly absorbable through the skin of the diseased part, effective in remarkably increasing and keeping the vitamin B1 concentration at the diseased part and exhibiting excellent effect for the remedy of neuralgia, myalgia, lumbago, etc., and the mitigation of the pain of the diseases. CONSTITUTION:The objective agent contains an allithiamine which is a disulfide- type vitamin derivative such as thiamine allyl disulfide or thiamine tetrahydrofurfuryl disulfide. The active component can be directly absorbed to the diseased part by coating or applying the external agent (e.g. ointment or poultice) to the skin of the diseased part. The B1 concentration can be maintained solely at the diseased part without increasing the concentration in the whole body by controlling the rate of absorption of allithiamine from the drug. Accordingly, the remedying effect can be extremely safely promoted.
Females are twice as likely to experience PTSD as compared to males. Although sex differences in prevalence are well-established, little is known about why such sex differences occur. Biological factors that vary with sex, including sex hormone production, may contribute to these differences. Considerable evidence links sex hormones, such as testosterone, to PTSD risk though less is known about the shared genetic underpinnings. The objective of the present study was to test for genetic relationships between testosterone and PTSD. To do so, we used summary statistics from large, publicly available genetic consortia to conduct linkage disequilibrium score regression to estimate the genetic correlations between PTSD and testosterone in males and females, and two-sample, bi-directional Mendelian randomization to examine potential causal relationships of testosterone on PTSD and the reverse. Heritability estimates of testosterone were significantly higher in males (0.17, SE = 0.02) than females (0.11, SE = 0.01; z = 2.46, p = 00.01). The correlation between testosterone and PTSD was negative in males (rg = -0.11, SE = 0.02, p = 6.7 x 10-6), but not significant in females (rg = 0.002, SE = 0.03, p = 0.95). MR analyses found no evidence of a causal effect of testosterone on PTSD or the reverse. Findings are consistent with phenotypic literature suggesting a relationship between testosterone and PTSD that may be sex-specific. This work provides early evidence of a relationship between testosterone and PTSD genotypically and suggests an avenue for future research that will enable a better understanding of disparities in PTSD.
BACKGROUND: Alveolar type II (ATII) cells have a stem cell potential in the adult lung and repair the epithelium after injury induced by harmful factors. Their damage contributes to emphysema development, characterized by alveolar wall destruction. Cigarette smoke is the main risk factor for this disease development.
METHODS: ATII cells were obtained from control non-smoker and smoker organ donors and emphysema patients. Isolated cells were used to study the role of PICT1 in this disease. Also, a cigarette smoke-induced murine model of emphysema was applied to define its function in disease progression further.
RESULTS: Decreased PICT1 expression was observed in human and murine ATII cells in emphysema. PICT1 was immunoprecipitated, followed by mass spectrometry analysis. We identified MRE11, which is involved in DNA damage repair, as its novel interactor. PICT1 and MRE11 protein levels were decreased in ATII cells in this disease. Moreover, cells with PICT1 deletion were exposed to cigarette smoke extract. This treatment induced cellular and mitochondrial ROS, cell cycle arrest, nuclear and mitochondrial DNA damage, decreased mitochondrial respiration, and impaired DNA damage repair.
CONCLUSIONS: This study indicates that PICT1 dysfunction can negatively affect genome stability and mitochondrial activity in ATII cells, contributing to emphysema development. Targeting PICT1 can lead to novel therapeutic approaches for this disease.
As with all therapeutic proteins, there is the potential for immunogenicity. Using an electrochemiluminescence (ECL)-based assay, 145 ANDEXXA-treated healthy subjects were tested for antibodies to ANDEXXA as well as for antibodies cross-reacting with factor X (FX) and FXa. Low titers of anti-ANDEXXA antibodies were observed in 26/145 healthy subjects (17%); 6% (9/145) were first observed at Day 30, with 20 subjects (14%) still having titers at the last time point (Days 44 to 48). To date, the pattern of antibody response in subjects in the ongoing ANNEXA-4 study has been similar to that observed in healthy volunteers. Of the 236 subjects with available samples, 6.8% (16/236) had antibodies against ANDEXXA. None of these anti-ANDEXXA antibodies were neutralizing. No neutralizing antibodies cross-reacting with FX or FXa were detected in healthy subjects (0/145) or in bleeding subjects (0/209) to date.

Detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ANDEXXA with the incidence of antibodies to other products may be misleading.
Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
A precipitation route to form nanoparticles with a hydrophilic core containing water soluble materials and a hydrophobic shell is described. The process requires a stabilizing polymer composed of more polar and more non-polar regions. These regions can be arranged as a linear block copolymer, or as a comb polymer with a linear or branched polar backbone and non-polar side chains or substituents. Nucleic acids, including DNA and RNA, as well as proteins, peptides, and polysaccharides or combinations can be encapsulated in the nanoparticle core. The encapsulation of nucleic acids can require partially or fully neutralizing the acid with a base to enhance the solubility of the nucleic acid in the process solvent stream. The core or the shell of the resulting nanoparticles can be crosslinked. The nanoparticles may be coated with additional polymer to bring them into water, or processed into microparticles or larger monoliths.
The present invention discloses an external-use medicine for treating peripheral neuritis and a preparation method thereof. The external-use medicine comprises raw wild aconite root, chuanxiong rhizome, notoginseng, etc. The present invention has the advantages that the medicine is capable of directly acting on diseased regions and has the advantages of reliability, safety and conspicuous curative effect. The present invention can relieve clinical symptoms of peripheral neuritis, such as numbness of limbs, pain, sensory disturbance, etc.; simultaneously, the present invention can improve microcirculatory disturbance of limbs, and nerve pathological states. The medicine breaks through the form that traditional Chinese medicines are prepared into external-use medicament forms such as tinctures, ointments, etc.; the medicine is prepared into gels and has the advantages of strong adhesiveness, good contact with skin, easy smearing operation, no oiliness sense, no pollution to clothes, easy cleaning, easy control of use quantity, portability, convenient storage and operation, etc.
Participants will be asked to maintain their habitual diet throughout the intervention. They will be provided with a brief document outlining the importance of a control group in research studies to maximise compliance. They will also receive £10/week vouchers during the intervention period and a further £60 on completion of the study to replicate voucher provision in the two intervention groups. Mimicking the voucher provision structure of the intervention groups will help to minimise participant drop out and will avoid any bias associated with differential financial remuneration between groups.
Myocardial infarction (MI) is a common cardiovascular disease caused by the blockages of coronary arteries. The visual inspection of electrocardiogram (ECG) is the main diagnosis pattern, while it is taxing and time-consuming. Motivated from state refinement module for long short term memory (SRM-LSTM), we proposed two improved state refinement frameworks based on LSTM and gated recurrent unit (GRU) called ISRM-LSTM and ISRM-GRU. Both are capable of adaptively refining current states of sample points in ECG with a message passing mechanism than existing LSTM. To evaluate the validity, both are installed into convolutional network architecture and standard LSTM, GRU and Residual networks are employed as control groups across the Physikalisch-Technische Bundesanstalt database. Empirical results confirm noticeable performance improvements than control groups and several existing algorithms with an accuracy of 99.1%. To our knowledge, both modules are the first attempt to consider the interaction characteristics into deep network and improve interpretability exhibiting considerable potentials on lightweight devices thanks to only utilization of three channel ECGs.
Nanotechnology has the potential to become a powerful tool in addiction medicine. The potential utility for passive, non-invasive wearable alcohol monitors is great and could play a major role in public safety as well as in both research, clinical, and treatment settings. Clinitech, LLC has developed LabPatch, an electronic bandage that continuously and imperceptibly samples interstitial fluid from the skin surface and measures relevant biomarkers in the fluid. The patch uses novel nanowire technology to sample the interstitial fluid from just underneath the skin and then uses an electrochemical reaction to measure either glucose or alcohol concentration. The participants' interstitial alcohol concentration (IAC) will be measured via LabPatch-alcohol at the same time points as blood samples so that a direct comparison can be made. Thus, the LabPatch-alcohol will be tested as the participant's BAC rises and falls through the legally intoxicated concentration (0.08%), and the goal is to match measures obtained via the prototype LabPatch-alcohol with whole blood alcohol concentrations. The LabPatch operational circuit lies on the underside of the bandage. The circuit surface is placed in contact with the skin by the application of the elastic adhesive bandage with a contact tension that provides modest pressure, as in the case of a conventional wound bandage. The temperature of the skin is measured electrically and the consistency of temperature is used to verify good contact and to monitor continued contact. The entire process takes 3-5 seconds to collect the sample, a pause for 1 sec and then 3 additional seconds to conduct the analysis.
This invention belongs to the bio-pharmacy technology field. The descripted construction contained the eukaryotic expression vector of bikunin, pSecTag2B-Bikunin, the product expressed by pSecTag2B-bikunin is the histidine tagged fusion protein with Myc. This invention applies the RT-PCR method to amplificate bikunin from human liver cell lines L02 and clone it to pMD18-T simple vector so as to contruct pMD18-T-bikunin. After enzyme cutting, PCR and sequencing and identification, subclones bikunin to eukaryotic expression vector pSecTag 2B. Enzyme cutting and PCR identification prove that the construction contains eukaryotic expression vector of BikuninpSecTag2B-bikunin successfully. Then transfecting NIH3T3 cells by calcium phosphate deposit. After 24 hours, western blot detects the culture supernatant of cell that condensed 25 times to prove there is expression of fusion protein. As a bio-agent, this protein can be used to cure tumor transfer.
According to the present invention, the production of repeated examination reports for each examination is limited in a report producing unit. In an ultrasonic diagnostic device according to the present invention, when a user provides an instruction to start producing a report, the report producing unit is activated. For example, the user inputs observations and the like into an examination report. When there is an instruction to finish producing the report from the user, the report producing unit produces an examination report indicating content at the time the instruction is received. When the examination is finished, the examination report is automatically transmitted to a work station. When an examination report is not produced at the time the examination is finished, the report producing unit automatically produces the examination report. In this case, the examination report is also automatically transmitted to the work station.
Hemodialysis (HD) is the main renal replacement therapy for patients with end-stage renal disease (ESRD), accounting for approximately 69% of all renal replacement therapies and 89% of all dialysis. However, factors such as unstable hemodynamics have led to the gradual loss of residual renal function (RRF) in HD patients. Research has found that 25%-67% of HD patients progress to anuria within the first 10 months of starting dialysis. The rate of loss is much faster than peritoneal dialysis（PD）, and the more frequent the dialysis sessions, the faster the loss of RRF. The loss of RRF not only affects the adequacy of dialysis and complications control but also impacts the patient's quality of life and survival. Unfortunately, until now, there have been no effective methods for early diagnosis and prediction of residual renal injury.

Traditionally, monitoring and diagnosing kidney damage have relied mainly on serum creatinine, urine output, and estimated glomerular filtration rate (eGFR). However, these indicators often occur after kidney damage has occurred, and their detection is delayed. The sensitivity for early diagnosis of kidney injury is low. By the time abnormalities are detected, the crucial treatment opportunity may have been missed. In addition, serum creatinine and other tests are susceptible to factors such as fluid dilution and reduced production in the body. Although some biomarkers for early diagnosis of acute kidney injury (AKI) have been developed domestically and internationally, most of them have not been applied in clinical practice and cannot be monitored in real-time. Moreover, these biomarkers may have significant differences in their generation between AKI and end-stage renal disease (ESRD) patients, making them unsuitable for early diagnosis and monitoring of residual renal injury in HD patients.

Near-infrared spectroscopy (NIRS) is a simple, safe, non-invasive, and real-time detection method that reflects organ perfusion by measuring changes in regional oxygen saturation. It is widely used in the diagnosis and prediction of neurological disorders, early prediction of AKI related to surgical procedures (cardiovascular, digestive, neurological, etc.), and monitoring of renal perfusion function after kidney transplantation. In theory, it can also be used for early diagnosis of residual renal injury in HD patients. This study is an exploratory research aiming to validate the value of NIRS in early diagnosis of residual renal injury by analyzing the correlation between renal oxygen saturation and urine output, as well as eGFR.
PURPOSE: To discuss the prevention and treatment of persistent epithelial defects after the most common refractive surgeries-photorefractive keratectomy, laser in situ keratomileusis, or small incision lenticule extraction.
METHODS: PubMed was used to search the medical literature.
RESULTS: Persistent epithelial defects are infrequent after photorefractive keratectomy, laser in situ keratomileusis, or small incision lenticule extraction. In the authors' opinion, any persistent epithelial defect present at 1 week or beyond after surgery should be treated aggressively with a properly fit bandage contact lens, lubrication with non-preserved artificial tears, and treatment of any eyelid abnormalities, including nocturnal lagophthalmos. Consideration should be given for presumptive treatment for herpes simplex virus or varicella zoster virus infection. If the persistent epithelial defect does not close within 2 weeks, then other measures should be considered, such as autologous serum drops, topical losartan, amniotic membranes, and topical human recombinant nerve growth factor to limit corneal scarring fibrosis and microbial infection.
CONCLUSIONS: Persistent epithelial defects are among the most feared complications of refractive surgery. Timely and aggressive treatment should be instituted to close the epithelium prior to the development of scarring fibrosis and/or microbial corneal infection. [J Refract Surg. 2024;40(2):e117-e124.].
The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
For dialysis patients, serum calcium, phosphorus, magnesium, and alkaline phosphatase should be determined periodically. For hypoparathyroid patients, serum calcium, phosphorus, and 24-hour urinary calcium should be determined periodically. For predialysis patients, serum calcium, phosphorus, alkaline phosphatase, creatinine, and intact PTH (iPTH) should be determined initially. Thereafter, serum calcium, phosphorus, alkaline phosphatase, and creatinine should be determined monthly for a 6-month period and then determined periodically. Intact PTH (iPTH) should be determined periodically every 3 to 4 months at the time of visits. During the titration period of treatment with calcitriol, serum calcium levels should be checked at least twice weekly (see  DOSAGE AND ADMINISTRATION ).
PURPOSE: To investigate the relationship between changes in pulmonary function (PF) and patient-reported outcomes (PROs) of lung cancer surgery.
METHODS: We recruited 262 patients who underwent lung resection for lung cancer, to evaluate the PROs, using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 and the Lung Cancer 13-question supplement (LC13). The patients underwent PF tests and PRO assessments preoperatively (Pre) and 1 year after surgery (Y1). Changes were calculated by subtracting the value at Pre from the value at Y1. We set two cohorts: patients under the ongoing protocol (Cohort 1) and patients who were eligible for lobectomy with clinical stage I lung cancer (Cohort 2).
RESULTS: Cohorts 1 and 2 comprised 206 and 149 patients, respectively. In addition to dyspnea, changes in PF were also correlated with scores for global health status, physical and role function scores, fatigue, nausea and vomiting, pain, and financial difficulties. Absolute correlation coefficient values ranged from 0.149 to 0.311. Improvement of emotional and social function scores was independent of PF. Sublobar resection preserved PF more than lobectomy did. Wedge resection mitigated dyspnea in both cohorts.
CONCLUSION: The correlation between PF and PROs was found to be weak; therefore, further studies are needed to improve the patient's postoperative experience.
The larval excretions/secretions (ES) of blowflies contain proteolytic enzymes and bacteria that assist with tissue breakdown. Decomposition fluid (DF) contains organic and inorganic waste products from cell death. This study investigated if human DNA recovery from blood was impacted by exposure to ES and DF over time. Lucilia sericata ES were collected daily from 50 larvae, and all available DF was collected from two fetal piglets left to decompose for 2 weeks. Daily for 3-5 days, 28 μL-30 μL of ES, DF, or a 1:1 mixture of the fluids was added to 30 μL of blood on cotton. Three bloodstains per treatment were sampled every 12 h up to 3 days and at 1 and 2 weeks after initial addition of fluid. No PCR inhibition was detected, but DNA degradation increased over time, primarily in samples exposed to ES and ES/DF mixtures. The amount of DNA recovered decreased over time, but generally more DNA was recovered from DF samples than other samples. Full profiles, or partial profiles suitable for routine database searching (14-39 alleles), were generated from all DF and ES samples and at least one mixture sample at all timepoints. Partial profiles of between 1 and 13 alleles were obtained from all other mixture samples, except one mixture sample which generated no profile. These findings indicate bloodstain evidence recovered from maggot-infested and/or decomposing bodies may generate forensically useful DNA evidence and should be analyzed as quickly as possible after collection or stored appropriately to prevent further degradation.